- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Monthly Erenumab may induce Remission of Medication-Overuse Headache in Chronic Migraine Patients: Study
A new study by Stewart Tepper and team showed that monthly 140 mg erenumab injections in individuals with non-opioid chronic migraine and drug overuse headaches resulted in medication overuse headache remission safely and effectively within 6 months.
Acute drug misuse is prevalent in migraine patients, which includes triptans, opioids, and both combination and basic analgesics. Medication overuse headache (MOH) is a recognized secondary headache disorder according to the International Classification of Headache Disorders (ICHD-3). It is characterized by prolonged overuse of acute headache medication(s) and a clinical observation of a significant worsening of an existing headache or the emergence of a new headache type in relation to the medication overuse.
The anticalcitonin gene-related peptide (CGRP) receptor monoclonal antibody erenumab-aooe was created for adult migraine prevention and has been effective in lowering monthly migraine days. This trial was set out to evaluate the safety and effectiveness of erenumab in patients with nonopioid CM-MOH.
This randomized, parallel-group, double-blind, placebo-controlled study lasted from October 7, 2019 to November 2, 2022, at 67 centers in North America, Europe, and Australia. Adults with CM-MOH who had failed at least one preventative therapy were eligible to participate. There were 992 individuals screened, with 620 enrolled. The main endpoint was MOH remission at month 6. The secondary end goals included the decrease from baseline in mean monthly acute headache prescription days (AHMD) at month 6 and the maintenance of MOH remission throughout the DBTP. Adverse events and alterations in vital signs served as safety endpoints.
The primary analysis sample consisted of 584 nonopioid-treated subjects with an average age of 44 years, 482 of whom were female (82.5%). Baseline demographics and illness characteristics were evenly distributed across groups. At month 6, 134 patients in the erenumab 140 mg group and 117 in the erenumab 70 mg group had achieved MOH remission when compared to 102 people enrolled in the placebo group (52.6%).
The usage of AHMD was similarly decreased in the erenumab groups compared to placebo. The least squares mean shift from baseline in average monthly AHMD was -9.4 (0.4) days in the erenumab 140 mg group and -7.8 (0.4) days in the erenumab 70 mg group when compared to -6.6 (0.4) days in the placebo group. verall, erenumab was successful in achieving and maintaining high rates of MOH remission, and the amount and quality of adverse events were consistent with the established safety profile of this medication.
Reference:
Tepper, S. J., Dodick, D. W., Lanteri-Minet, M., Dolezil, D., Gil-Gouveia, R., Lucas, C., Piasecka-Stryczynska, K., Szabó, G., Mikol, D. D., Chehrenama, M., Chou, D. E., Yang, Y., & Paiva da Silva Lima, G. (2024). Efficacy and safety of erenumab for nonopioid medication overuse headache in chronic migraine: A phase 4, randomized, placebo-controlled trial. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2024.3043
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751